Applied DNA Sciences Partners with B2i Digital to Showcase Strategic Rebrand and BNB Treasury Strategy

Applied DNA Sciences, Inc. has been named a B2i Digital Featured Company as it completes a strategic rebrand reflecting its expansion from nucleic acid manufacturing to a broader platform integrating digital asset management. The company's transformation centers on implementing a yield-focused BNB digital asset treasury strategy designed to enhance shareholder value while continuing to leverage its proprietary nucleic acid production expertise as a supporting technology platform. David Shapiro, CEO of B2i Digital, expressed enthusiasm about featuring Applied DNA Sciences during this evolutionary phase, noting that the company's shift toward a BNB-centric digital asset treasury underscores its commitment to innovation in corporate finance and shareholder alignment.

Clay Shorrock, CEO of Applied DNA Sciences, emphasized that partnering with B2i Digital enables the company to share its transformation and long-term vision with a much wider investor audience. As Applied DNA executes on its BNB treasury strategy, the collaboration with B2i Digital will help investors understand how the approach to digital asset management supports both growth and balance-sheet strength. The company previously announced approximately $27 million in aggregate gross proceeds to implement its BNB treasury strategy, managed under a five-year Strategic Digital Assets Services Agreement with Cypress LLC and a five-year Strategic Advisor Agreement with Cypress Management LLC.

The strategic pivot is further evidenced by the company's recent ticker symbol change from APDN to BNBX effective October 7, 2025, directly reflecting its digital asset treasury strategy. Through its LineaRx subsidiary, Applied DNA continues to commercialize its LineaDNA, LineaRNAP, and LineaIVT platforms, which enable cell-free manufacturing of DNA and RNA for therapeutics and diagnostics. This dual approach is designed to generate yield and token accumulation within the Binance ecosystem while maintaining a foundation of operational technology expertise.

As a B2i Digital Featured Company, Applied DNA will be introduced to retail and institutional investors across B2i Digital's multi-channel network, which includes platforms such as https://www.linkedin.com/company/b2i-digital, https://x.com/b2idigital, and https://www.facebook.com/b2idigital. The campaign will feature dedicated digital content, investor presentations, and company updates designed to highlight Applied DNA's strategic transformation and communicate its evolving growth narrative at scale. B2i Digital's proprietary network of over 1.4 million market participants provides Applied DNA with significant exposure to both retail and institutional investors interested in innovative corporate finance strategies.

The company's transformation represents a notable example of how traditional businesses are integrating digital asset strategies into their core operations. While maintaining its biotechnology capabilities through platforms available at https://adnas.com, Applied DNA's shift toward BNB-focused treasury management signals a broader trend of companies exploring digital assets as part of their capital allocation and value creation strategies. This strategic rebranding could potentially influence how other publicly traded companies approach digital asset integration and treasury management in the evolving financial landscape.